| Antibiotics for the treatment of irritable bowel syndrome. | |
| | |
MedLine Citation:
|
PMID: 22298980 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with an estimated worldwide prevalence of 10-20%. IBS can be associated with severe gastrointestinal symptoms, including abdominal pain, bloating, and altered bowel function. Although the causes of IBS remain undefined, recent research has increasingly suggested roles for gut flora in IBS. These roles involve postinfectious IBS, which can occur after a single episode of acute gastroenteritis, and small intestinal bacterial overgrowth, in which elevated populations of aerobic and anaerobic bacteria cause abdominal pain and altered bowel function. More recently, potential roles for methanogens in contributing to IBS subtypes have also been identified. In this paper, we review the different mechanisms by which gut flora may contribute to IBS and also discuss the efficacy and safety of various antibiotic therapies for treating IBS symptoms. |
| | |
Authors:
|
Robert J Basseri; Stacy Weitsman; Gillian M Barlow; Mark Pimentel |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Gastroenterology & hepatology Volume: 7 ISSN: 1554-7914 ISO Abbreviation: Gastroenterol Hepatol (N Y) Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2012-02-02 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101262648 Medline TA: Gastroenterol Hepatol (N Y) Country: United States |
Other Details:
|
Languages: eng Pagination: 455-93 Citation Subset: - |
Affiliation:
|
Dr. Basseri, Ms. Weitsman, and Dr. Barlow are affiliated with the GI Motility Program at Cedars-Sinai Medical Center in Los Angeles, California, where Dr. Pimentel serves as Director. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic value of liver fibrosis biomarkers: a meta-analysis.
Next Document: Immune tolerant hepatitis B: a clinical dilemma.